|
US4302589A
(en)
*
|
1980-05-08 |
1981-11-24 |
American Cyanamid Company |
Cis-mono and disubstituted-2-methyl-3-[(piperazinyl) and (piperidino)ethyl]indolines, intermediates for their preparation and methods of preparation
|
|
CN1329493A
(zh)
|
1998-12-02 |
2002-01-02 |
辉瑞产品公司 |
恢复p53家族蛋白质的构象稳定性的方法和组合物
|
|
US6770652B2
(en)
|
2001-10-18 |
2004-08-03 |
Duquesne University Of The Holy Ghost |
Multiple acting anti-angiogenic and cytotoxic compounds and methods for using the same
|
|
CA2511625A1
(en)
*
|
2002-12-23 |
2004-07-15 |
City Of Hope |
Modified vaccinia ankara expressing p53 in cancer immunotherapy
|
|
JP2008505910A
(ja)
|
2004-07-08 |
2008-02-28 |
ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド |
Ｐｋｃ−シータのインヒビターとして有用なピリミジン誘導体
|
|
WO2006136823A1
(en)
|
2005-06-21 |
2006-12-28 |
Astex Therapeutics Limited |
Heterocyclic containing amines as kinase b inhibitors
|
|
US8822420B2
(en)
|
2008-03-13 |
2014-09-02 |
Universita Degli Studi Di Trieste |
Peptides and aptamers thereof as specific modulators of mutant p53 function
|
|
GB0808282D0
(en)
|
2008-05-07 |
2008-06-11 |
Medical Res Council |
Compounds for use in stabilizing p53 mutants
|
|
AU2009322774A1
(en)
|
2008-12-03 |
2011-06-30 |
Via Pharmaceuticals, Inc |
Inhibitors of diacylglycerol acyltransferase
|
|
DK2410844T3
(en)
|
2009-03-27 |
2016-07-04 |
Merck Sharp & Dohme |
Inhibitors of hepatitis C virus replication
|
|
DE102010049877A1
(de)
|
2010-11-01 |
2012-05-03 |
Merck Patent Gmbh |
7-((1,2,3)Triazol-4-yl)-pyrrolo(2,3) pyrazinderivate
|
|
RU2598842C2
(ru)
|
2011-01-20 |
2016-09-27 |
Мерк Шарп Энд Домэ Корп. |
Антагонисты рецептора минералокортикоидов
|
|
GB201110390D0
(en)
|
2011-06-20 |
2011-08-03 |
Medical Res Council |
Compounds for use in stabilising p53 mutants
|
|
US9517252B2
(en)
|
2011-09-09 |
2016-12-13 |
Agency For Science, Technology And Research |
p53 activating peptides
|
|
EP2809656A2
(en)
|
2011-12-28 |
2014-12-10 |
Allergan, Inc. |
Benzimidazole derivatives as selective blockers of persistent sodium current
|
|
US8822689B2
(en)
|
2012-09-19 |
2014-09-02 |
Merial Limited |
Aryloazol-2-yl cyanoethylamino compounds, method of making and method of using thereof
|
|
WO2015089187A1
(en)
*
|
2013-12-10 |
2015-06-18 |
Incuron, Llc |
Methods of modulating various biomarkers with curaxins
|
|
EP3145512B1
(en)
|
2014-05-19 |
2019-07-17 |
Jiangsu Hengrui Medicine Co., Ltd. |
Substituted ethynyl heterobicyclic compounds as tyrosine kinase inhibitors
|
|
US20170184604A1
(en)
|
2014-05-22 |
2017-06-29 |
The General Hospital Corporation |
Dd1alpha receptor and uses thereof in immune disorders
|
|
WO2016004513A1
(en)
|
2014-07-11 |
2016-01-14 |
Simon Fraser University |
Anti-bacterial pyruvate kinase modulator compounds, compositions, uses and methods
|
|
CN104672241B
(zh)
|
2015-01-29 |
2018-04-24 |
王磊 |
吡咯并[2,3-d]嘧啶类化合物及其用途
|
|
EP3328418A1
(en)
|
2015-07-29 |
2018-06-06 |
Novartis AG |
Combination therapies comprising antibody molecules to pd-1
|
|
US20170114098A1
(en)
|
2015-09-03 |
2017-04-27 |
Aileron Therapeutics, Inc. |
Peptidomimetic macrocycles and uses thereof
|
|
WO2017079746A2
(en)
*
|
2015-11-07 |
2017-05-11 |
Multivir Inc. |
Methods and compositions comprising tumor suppressor gene therapy and immune checkpoint blockade for the treatment of cancer
|
|
KR102868217B1
(ko)
|
2016-02-19 |
2025-10-14 |
피엠브이 파마슈티컬스 인코포레이티드 |
돌연변이 p53 기능을 회복시키는 방법 및 화합물
|
|
US10870640B2
(en)
*
|
2016-04-08 |
2020-12-22 |
Institute For Cancer Research |
Prodigiosin analogs and methods of use
|
|
US20180008688A1
(en)
*
|
2016-07-06 |
2018-01-11 |
Augusta University Research Institute, Inc. |
Method and compositions for enhancing immunotherapeutic treatment of a cancer
|
|
EP3528816A4
(en)
|
2016-10-21 |
2020-04-08 |
Nimbus Lakshmi, Inc. |
TYK2 INHIBITORS AND USES THEREOF
|
|
JP7103342B2
(ja)
*
|
2017-03-23 |
2022-07-20 |
日本電産トーソク株式会社 |
ポンプ装置
|
|
US20200071326A1
(en)
|
2017-04-14 |
2020-03-05 |
Syros Pharmaceuticals, Inc. |
Tam kinase inhibitors
|
|
US20190002460A1
(en)
|
2017-06-28 |
2019-01-03 |
The Regents Of The University Of Michigan |
Small molecule inhibitors of egfr and pi3k
|
|
KR102577241B1
(ko)
|
2017-12-28 |
2023-09-11 |
주식회사 대웅제약 |
카이네이즈 저해제로서의 아미노-플루오로피페리딘 유도체
|
|
US11203598B2
(en)
*
|
2018-01-24 |
2021-12-21 |
Institute For Cancer Research |
Compounds for repressing cancer cell growth
|
|
WO2019165576A1
(en)
|
2018-02-27 |
2019-09-06 |
President And Fellows Of Harvard College |
Methods for treating cancer and protecting renewable tissues
|
|
KR20210062044A
(ko)
*
|
2018-09-20 |
2021-05-28 |
아프레아 테라퓨틱스 에이비 |
퀴누클리딘-3-온 유도체와 암 치료에서 이의 용도
|
|
US12274784B2
(en)
*
|
2018-10-12 |
2025-04-15 |
Synergene Therapeutics, Inc. |
Methods for reducing side effects of immunotherapy
|
|
US20220184087A1
(en)
*
|
2019-03-28 |
2022-06-16 |
The Penn State Research Foundation |
Methods and compositions relating to treatment of cancer
|
|
EP4031136A1
(en)
|
2019-09-18 |
2022-07-27 |
Aprea Therapeutics AB |
Combination treatment with a p53 reactivator and an inhibitor of an antiapoptotic bcl-2 family protein
|
|
DK4034104T3
(da)
|
2019-09-23 |
2025-10-06 |
Pmv Pharmaceuticals Inc |
Metoder og forbindelser til genoprettelse af mutant p53-funktion
|
|
WO2021087096A1
(en)
|
2019-11-01 |
2021-05-06 |
The Regents Of The University Of California |
P53 modulators and uses thereof
|
|
TW202128156A
(zh)
|
2019-11-14 |
2021-08-01 |
美商夸格智財控股有限公司 |
用於癌症治療之btk抑制劑及mdm2抑制劑之組合
|
|
WO2021113644A1
(en)
|
2019-12-05 |
2021-06-10 |
Multivir Inc. |
Combinations comprising a cd8+ t cell enhancer, an immune checkpoint inhibitor and radiotherapy for targeted and abscopal effects for the treatment of cancer
|
|
WO2021170772A1
(en)
|
2020-02-26 |
2021-09-02 |
Aprea Therapeutics Ab |
Combination treatment with a p53 reactivator and an inhibitor of cd47 mediated signaling
|
|
WO2021207598A1
(en)
|
2020-04-10 |
2021-10-14 |
Aprea Therapeutics, Inc. |
Combination treatment with an agonist of p53 and a second therapeutic agent
|
|
WO2021231474A1
(en)
*
|
2020-05-12 |
2021-11-18 |
Pmv Pharmaceuticals, Inc. |
METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION
|
|
US12570645B2
(en)
|
2020-06-22 |
2026-03-10 |
Pmv Pharmaceuticals, Inc. |
Uses of p53 x-ray co-crystal structures
|
|
CA3183025A1
(en)
|
2020-06-24 |
2021-12-30 |
Melissa Dumble |
Companion diagnostic tool for mutant p53 reactivating compounds
|
|
US20230049952A1
(en)
|
2020-06-24 |
2023-02-16 |
Pmv Pharmaceuticals, Inc. |
Methods and compounds for restoring mutant p53 function
|